National Vision Holdings, Inc. (EYE) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
46/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseEYE / S&P -26.60% / 15.20% |
LoseEYE / S&P 7.84% / 15.00% |
LoseEYE / S&P -438.89% / 50.40% |
| 2026-Q11/3 |
WinEYE / S&P 0.31% / -4.33% |
LoseEYE / S&P 9.20% / 11.30% |
LoseEYE / S&P -272.73% / 27.70% |
| 2025-Q41/3 |
LoseEYE / S&P -11.55% / 2.65% |
WinEYE / S&P 9.00% / 9.00% |
LoseEYE / S&P -202.78% / 13.40% |
| 2025-Q32/3 |
WinEYE / S&P 26.86% / 8.12% |
WinEYE / S&P 6.33% / 4.61% |
LoseEYE / S&P -85.71% / 13.45% |
| 2025-Q22/3 |
WinEYE / S&P 80.05% / 10.94% |
WinEYE / S&P 5.08% / 4.83% |
LoseEYE / S&P -82.69% / 10.63% |
| 2025-Q11/3 |
WinEYE / S&P 22.65% / -4.27% |
LoseEYE / S&P 4.31% / 4.98% |
LoseEYE / S&P -64.52% / 10.57% |
| 2024-Q40/3 |
LoseEYE / S&P -4.49% / 2.41% |
LoseEYE / S&P 0.60% / 5.25% |
LoseEYE / S&P -58.14% / 6.15% |
| 2024-Q31/3 |
LoseEYE / S&P -16.65% / 5.89% |
WinEYE / S&P 20.50% / 5.89% |
LoseEYE / S&P -72.37% / 6.11% |
| 2024-Q21/3 |
LoseEYE / S&P -40.93% / 4.28% |
WinEYE / S&P 15.02% / 5.38% |
LoseEYE / S&P -415.15% / 5.12% |
| 2024-Q11/3 |
LoseEYE / S&P 5.88% / 10.56% |
WinEYE / S&P 8.34% / 5.71% |
LoseEYE / S&P -344.74% / 5.59% |
| 2023-Q42/3 |
WinEYE / S&P 29.36% / 11.69% |
WinEYE / S&P 10.20% / 6.81% |
LoseEYE / S&P -272.00% / 7.78% |
| 2023-Q30/3 |
LoseEYE / S&P -33.39% / -3.27% |
LoseEYE / S&P -25.55% / 7.52% |
LoseEYE / S&P -208.57% / -5.03% |
| 2023-Q21/3 |
WinEYE / S&P 28.93% / 8.74% |
LoseEYE / S&P -23.27% / 9.50% |
LoseEYE / S&P -67.00% / -8.57% |
| 2023-Q10/3 |
LoseEYE / S&P -51.39% / 7.50% |
LoseEYE / S&P -21.00% / 10.77% |
LoseEYE / S&P -70.77% / -15.69% |
| 2022-Q41/3 |
WinEYE / S&P 18.71% / 7.56% |
LoseEYE / S&P -20.91% / 11.88% |
LoseEYE / S&P -65.28% / -17.99% |
| 2022-Q31/3 |
WinEYE / S&P 18.73% / -4.88% |
LoseEYE / S&P -4.01% / 13.47% |
LoseEYE / S&P -60.67% / -1.41% |
| 2022-Q20/3 |
LoseEYE / S&P -36.88% / -16.10% |
LoseEYE / S&P -1.58% / 13.71% |
LoseEYE / S&P -42.86% / 11.04% |
| 2022-Q12/3 |
LoseEYE / S&P -9.21% / -4.60% |
WinEYE / S&P 16.71% / 15.97% |
WinEYE / S&P 66.67% / 42.23% |
| 2021-Q42/3 |
LoseEYE / S&P -15.47% / 11.03% |
WinEYE / S&P 21.48% / 15.00% |
WinEYE / S&P 242.86% / 96.40% |
| 2021-Q33/3 |
WinEYE / S&P 11.03% / 0.58% |
WinEYE / S&P 29.78% / 10.77% |
WinEYE / S&P 4350.00% / 69.42% |
| 2021-Q22/3 |
WinEYE / S&P 16.66% / 8.55% |
WinEYE / S&P 32.13% / 6.58% |
LoseEYE / S&P -572.97% / 51.81% |
| 2021-Q12/3 |
LoseEYE / S&P -3.22% / 6.17% |
WinEYE / S&P 2.51% / -1.06% |
WinEYE / S&P 151.61% / 7.39% |
| 2020-Q43/3 |
WinEYE / S&P 18.44% / 12.15% |
WinEYE / S&P -0.73% / -3.72% |
WinEYE / S&P 5.00% / -33.42% |
| 2020-Q31/3 |
WinEYE / S&P 25.29% / 8.93% |
LoseEYE / S&P -3.67% / -2.04% |
LoseEYE / S&P -63.64% / -27.10% |
| 2020-Q21/3 |
WinEYE / S&P 57.16% / 20.54% |
LoseEYE / S&P -4.32% / -0.46% |
LoseEYE / S&P -331.25% / -27.11% |
| 2020-Q12/3 |
LoseEYE / S&P -40.12% / -19.60% |
WinEYE / S&P 8.98% / 3.47% |
WinEYE / S&P 63.16% / -14.75% |
| 2019-Q43/3 |
WinEYE / S&P 34.73% / 9.07% |
WinEYE / S&P 12.20% / 5.36% |
WinEYE / S&P 37.93% / 2.99% |
| 2019-Q31/3 |
LoseEYE / S&P -21.67% / 1.70% |
WinEYE / S&P 11.69% / 5.02% |
LoseEYE / S&P -88.30% / 0.21% |
| 2019-Q21/3 |
LoseEYE / S&P -2.23% / 4.30% |
WinEYE / S&P 11.81% / 6.64% |
LoseEYE / S&P -82.42% / 8.65% |
| 2019-Q11/3 |
LoseEYE / S&P 11.57% / 13.65% |
WinEYE / S&P 12.50% / 8.12% |
LoseEYE / S&P -73.61% / 14.29% |
| 2018-Q41/3 |
LoseEYE / S&P -37.59% / -13.52% |
WinEYE / S&P 11.75% / 9.05% |
LoseEYE / S&P -58.57% / 18.23% |
| 2018-Q33/3 |
WinEYE / S&P 23.43% / 7.71% |
WinEYE / S&P 12.94% / 10.21% |
WinEYE / S&P 944.44% / 19.06% |
| 2018-Q23/3 |
WinEYE / S&P 13.18% / 3.43% |
WinEYE / S&P 13.66% / 9.03% |
WinEYE / S&P 727.27% / 14.46% |
| 2018-Q10/3 |
LoseEYE / S&P -20.44% / -0.76% |
LoseEYE / S&P EYE unavailable / 7.68% |
LoseEYE / S&P EYE unavailable / 12.46% |
| 2017-Q40/3 |
LoseEYE / S&P EYE unavailable / 6.64% |
LoseEYE / S&P EYE unavailable / 7.03% |
LoseEYE / S&P EYE unavailable / 13.82% |
| 2017-Q30/3 |
LoseEYE / S&P EYE unavailable / 4.48% |
LoseEYE / S&P EYE unavailable / 5.68% |
LoseEYE / S&P EYE unavailable / 17.57% |
| 2017-Q20/3 |
LoseEYE / S&P EYE unavailable / 3.09% |
LoseEYE / S&P EYE unavailable / 4.83% |
LoseEYE / S&P EYE unavailable / 17.74% |
| 2017-Q10/3 |
LoseEYE / S&P EYE unavailable / 6.07% |
LoseEYE / S&P EYE unavailable / 3.67% |
LoseEYE / S&P EYE unavailable / 13.32% |
| 2016-Q40/3 |
LoseEYE / S&P EYE unavailable / 3.82% |
LoseEYE / S&P EYE unavailable / 2.09% |
LoseEYE / S&P EYE unavailable / 7.05% |
| 2016-Q30/3 |
LoseEYE / S&P EYE unavailable / 3.85% |
LoseEYE / S&P EYE unavailable / 0.20% |
LoseEYE / S&P EYE unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | EYE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -22.10% | 20.78% |
| Annualized return | -22.10% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | EYE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.10% | 83.14% |
| Annualized return | -21.45% | 12.86% |
10Y · 2017-10-27 to 2026-08-27
| Metric | EYE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -36.52% | 319.30% |
| Annualized return | -4.44% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| RxSight, Inc. (RXST) | United States | $0.197B | |
| Innovative Eyewear Inc (LUCY) | United States | $0.008B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |